Emil Assentato - Nukkleus CEO and Presidentident

NUKKW Stock   0.01  0.02  67.44%   

CEO

Emil Assentato is CEO and Presidentident of Nukkleus
Age 74
Address 525 Washington Boulevard, Jersey City, NJ, United States, 07310
Phone212-791-4663
Webhttps://www.nukk.com

Emil Assentato Latest Insider Activity

Tracking and analyzing the buying and selling activities of Emil Assentato against Nukkleus stock is an integral part of due diligence when investing in Nukkleus. Emil Assentato insider activity provides valuable insight into whether Nukkleus is net buyers or sellers over its current business cycle. Note, Nukkleus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nukkleus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Nukkleus Management Efficiency

The company has return on total asset (ROA) of (1.1502) % which means that it has lost $1.1502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7499) %, meaning that it generated substantial loss on money invested by shareholders. Nukkleus' management efficiency ratios could be used to measure how well Nukkleus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.48 in 2024. Return On Capital Employed is likely to climb to -1.12 in 2024. At this time, Nukkleus' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 4.5 M in 2024, whereas Non Currrent Assets Other are likely to drop (13.9 M) in 2024.

Similar Executives

Found 5 records

CEO Age

Brian KocherSunOpta
55
Thomas LingelbachValneva SE ADR
61
Charles ProberNETGEAR
53
Dara KhosrowshahiUber Technologies
54
Joseph EnnenSunOpta
56
Nukkleus (NUKKW) is traded on NASDAQ Exchange in USA. It is located in 525 Washington Boulevard, Jersey City, NJ, United States, 07310 and employs 12 people. Nukkleus was previously known as Brilliant Acquisition and was traded on NASDAQ Exchange under the symbol BRLIW. Nukkleus is listed under Application Software category by Fama And French industry classification.

Management Performance

Nukkleus Leadership Team

Elected by the shareholders, the Nukkleus' board of directors comprises two types of representatives: Nukkleus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nukkleus. The board's role is to monitor Nukkleus' management team and ensure that shareholders' interests are well served. Nukkleus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nukkleus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jamal Khurshid, COO Director
Emil Assentato, CEO and Presidentident
Menachem Shalom, CEO Director
Andrew MBA, Chief Officer
Shawn Dilkes, Chief Officer

Nukkleus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nukkleus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Nukkleus Stock Analysis

When running Nukkleus' price analysis, check to measure Nukkleus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nukkleus is operating at the current time. Most of Nukkleus' value examination focuses on studying past and present price action to predict the probability of Nukkleus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nukkleus' price. Additionally, you may evaluate how the addition of Nukkleus to your portfolios can decrease your overall portfolio volatility.